The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Home | Video pages | Webcast | Echocardiography or Cardiac Magnetic resonance Imaging (or both) for cardiac assessment in CKD patients?

Echocardiography or Cardiac Magnetic resonance Imaging (or both) for cardiac assessment in CKD patients?